Introduction
Glioblastoma multiforme (GBM) is a rapidly growing and uniformly lethal brain tumor. Glioblastomas are categorized as the highest grade of astrocytic neoplasm (Kleiheus and Caveness, 1997) . Primary glioblastomas, which are detected at first presentation, are typically seen in older patients, 55-60 years (reviewed by Kleihues and Ohgaki, 1999; Nozaki et al., 1999) . Of all tumors of neuroepithelial origin, the incidence of GBM in adults over 20 comprises 61% men and 56% women (US Cancer Statistics, 2005) .
With the exception of pilocytic astrocytomas (grade I), virtually all astrocytomas progress to higher-grade neoplasms (Kleiheus and Caveness, 1997) . In highergrade neoplasms, the rate of cellular proliferation increases, as does the degree of infiltration. Thus, as the highest grade tumors, GBMs exhibit the highest rate of proliferation and the most extensive infiltration. They also exhibit neovascularization and necrosis; however, it is their rapid rate of proliferation and aggressive invasion that underlie the mortality rate of virtually 100%.
A number of molecular markers have been associated with primary GBMs. In particular, 50% of primary GBMs are associated with epidermal growth factor receptor (EGFR) abnormalities (Nozaki et al., 1999; Mischel and Cloughesy, 2003; Houillier et al., 2006) . EGFR dysregulation in GBMs arises from EGFR gene (egfr) amplification, mutation and overexpression. All of these lead to excessive activation of downstream signal cascades, which in turn leads to rapid proliferation. The association of primary GBMs with EGFR has spurred the development of novel GBM chemotherapeutic agents that prevent EGFR signaling, such as monoclonal antibodies and small molecule tyrosine kinase inhibitors. Monoclonal antibodies have been developed that target growth factor receptors in a number of tumor types, and several of these have been studied for their applicability to GBMs (reviewed by Mischel and Cloughesy, 2003) . For example, cetuximab is a monoclonal antibody directed against EGFR. In mice, cetuximab has been shown to prolong survival, alone and in combination with radiation therapy (Eller et al., 2005) . Small molecule tyrosine kinase inhibitors have been directed against receptor tyrosine kinases, such as EGFR (reviewed by Shawver et al., 2002) . One specific inhibitor directed against EGFR, IRESSA (Astra-Zeneca, Wilmington, DE, USA), is now in clinical trials.
GBM proliferation has also been linked to kinases further downstream. In particular, members of the protein kinase C family (PKCs). There are three classes of PKCs: classic, PKC a, bI, bII, g; novel, d, e, Z, y and atypical, z and l/i. The mechanism of PKC activation depends on the isoform. Activation of classic PKCs requires Ca 2 þ ; activation of novel and atypical PKC isozyme activity are Ca 2 þ independent. Both classic and novel PKCs are activated by diacyl glycerol and phorbol esters (Baltuch et al., 1995) . Different PKC isoforms have been associated with different proliferation rates of neoplastic astrocytes. For example, in the U-251 MG glioblastoma cell line (U-251), Mishima et al. (1994) , reported that stable overexpression of PKC-g is associated with increased growth, whereas PKC-d is associated with decreased growth. Therefore, a given PKC isotype may dictate the degree of the proliferative response to phorbol 12-myristate 13-acetate (PMA).
Previously, we reported that expression of the novel isoform PKC-Z correlates with a high degree of proliferation in glioblastoma cell lines. We compared the response to PMA in U-251 cell to that of U-1242 cells. U-251 cells express PKC-Z (Mishima et al., 1994) but the U-1242 line do not (Hussaini et al., 2000) . PMA increases the mitogenic response in U-251 cells, and inhibits the mitogenic response in U-1242 cells. Furthermore, stable expression of PKC-Z in the U-1242 cells (U-1242-PKC-Z) confers a PMA growth-stimulated phenotype similar to that of the U-251 (Hussaini et al., 2000) . These data suggest that the novel PKC-Z isozyme confers an increased proliferative response to mitogenic stimuli. Thus, we sought to identify downstream targets of PKC-Z.
When the major phosphorylation cascades were first elucidated, the primary PKC downstream transcription factor target was considered to be the activator protein-1 complex (AP-1), composed of jun:jun homodimers or jun:fos heterodimers (Karin and Smeal, 1992) . However, it is now known that members of all three classes of PKC isoforms can activate extracellular signal-regulated kinase (ERK) and MAPK/ERK kinase-1 (MEK-1) (Schonwasser et al., 1998b) . This latter pathway is of particular interest in this study, in that the ERK signaltransduction pathway is activated by EGFR. An important downstream transcription factor target of ERK1/2 is Elk-1, a member of the ets family of transcription factors (Yordy and Muise-Helmericks, 2000) . Therefore, we decided to assess the ability of PKC-Z to activate the classic PKC target AP-1, and/or the ERK target, Elk-1.
Results
Overexpression of AP-1 components, c-jun and c-fos, fails to enhance transcriptional activity in U-251 cells A prototypic PKC target is the AP-1 complex; this is formed of jun:jun homodimers or jun:fos heterodimers. Such dimers regulate cell proliferation and apoptosis, and are thus implicated in the oncogenesis of many malignancies (reviewed by Eferl and Wagner, 2003; Young et al., 2003; Hess et al., 2004; Milde-Langosch, 2005) .
To determine if PKC stimulation would activate transcription through an AP-1 complex, we transfected U-251 cells with an AP-1-activated reporter construct, Coll73:LUC (Figure 1, top) (Lopez et al., 1993; Uht et al., 1997) . A c-jun expression vector (Uht et al., 1997) was co-transfected. Surprisingly, c-jun blocked PMA transcriptional activity (Figure 1a ). To determine if a different amount of c-jun could sustain stimulation, we transfected cells with increasing amounts of c-jun. Over a range of mass (0.1-3 mg), transcriptional activation Elk-1 mediates PKC-g-induced proliferation RM Uht et al was not observed (data not shown). We then assessed the effects of c-fos, again by titrating in a range of mass. Additionally, we co-transfected c-fos with c-jun. In neither case did c-fos alter transcriptional activity (data not shown). Thus, U-251 cells, which express endogenous PKC-Z do not support AP-1-activated transcription, as measured by a reporter assay. c-jun transcriptional repression might be explained by squelching. Squelching occurs when a transcription factor is present in such abundance that it titrates necessary co-regulators, or components of the basal transcriptional machinery (Gill and Ptashne, 1988) . Thus, if U-251 cells contain an abundance of c-jun, its overexpression might lead to transcriptional inhibition. Thus, we compared wild-type c-jun to a c-jun mutated at phosphorylation sites critical for its activation (Ser63/ 73), which should act as a c-jun dominant negative. As shown in Figure 1a , the c-jun mutant abolished repression. Thus, c-jun inhibition of PMA-stimulated transcriptional activity may be explained by squelching.
We then asked if the proliferative activity of the U-251 cells paralleled the transcriptional response. Transfected c-jun reduced the proliferation rate, and the reduction was attenuated by transfection with c-jun 63/73 ( Figure 1b) . Thus, c-jun regulates transcriptional activity and the proliferative response to PMA in U-251 cells; however, the effect is repressive rather than stimulatory.
The transcription factor Elk-1 is a downstream target of PKC-Z Because the EGFR is overexpressed in approximately 50% of primary glioblastomas (Mischel and Cloughesy, 2003; Eller et al., 2005) , we asked if an EGFR downstream target could be regulated by PKC-Z. Thus, we evaluated Elk-1.
Because transiently transfected Elk-1 could increase transcription activity of a reporter indirectly, we used a GAL-based transfection assay. We co-transfected a GAL DBD: Elk-1-activation domain fusion expression vector with a (GAL-RE) 5 : luciferase reporter construct ( Figure 2a ). Unlike the PMA effect on c-jun, PMA activated Gal:Elk-1 induced transcription, and did so in a pattern that reflected cellular PKC-Z status . PMA elicited a transcriptional response in U-251 MG cells (Figure 2b ), which endogenously express PKC-Z. PMA had little effect in U-1242 MG cells (U-1242; Figure 2c ), but elicited activity in U-1242 cells that stably express PKC-Z (U-1242-Z; Figure 2d ). To ensure that these responses were not owing to a GAL fusion, we repeated the experiments with GAL-c-jun. The GAL-c-jun data paralleled those of the c-jun expression vector ( Figure 1a) ; overexpressed c-jun blocked PMA-stimulated transcription (not shown). Together, the data suggest that in glioblastoma lines that express PKC-Z, Elk-1 is a downstream transcription factor target activated by PMA.
PKC-Z expression in the U-1242 glioblastoma cell line is associated with ERK1/2 phosphorylation It is established that activation of Elk-1 involves activated ERK1/2, that is, phosphorylated-ERK (pERK1/2). It has also been shown that PKC-Z activates ERK via MEK in Cos-7 cells (Schonwasser et al., 1998a) ; however, it is not known if ERK is a downstream target of PKC-Z in U-1242 or U-251 glioblastoma cells. As shown in Figure 3a , the wild-type U-1242 PKC-Z-deficient cell line expressed pERK. The U-1242-PKC-Z cell line expressed higher levels of pERK1 and 2 (lane 2). To determine if the phosphorylation of ERK1/2 was mediated through MEK1, we preincubated the U-1242-Z cells with the MEK inhibitor, U0126. Doing so reduced pERK1/2 to levels observed in the 1242 wild-type (lane 3 vs lane 1). Across these three groups, the amount of total ERK1/2 stayed constant ( Figure 3a, lower panel) . Thus, the PKC-Z effect is one of ERK phosphorylation rather than increased cellular ERK levels.
We next compared U0126 to bisindolyl maleimide (BIM) for its ability to block phosphorylation. BIM blocks both classic and novel PKC isoforms, including PKC-Z. As with U0126, treatment with BIM reduced the level of pERK1/2 (Figure 3b ). Taken together, the data suggest that ERK is downstream of PKC-Z.
Because ERK1/2 also targets P90rsk, which in turn may phosphorylate cAMP response-element-binding (CREB) (Frodin and Gammeltoft, 1999) , we sought to determine if the PKC-Z-MEK1/2-ERK1/2 pathway Elk-1 mediates PKC-g-induced proliferation RM Uht et al specifically activated Elk-1. The presence of PKC-Z in the U-1242 cells failed to alter basal or PMA-stimulated levels of pP90rsk, or total P90rsk (Figure 4a ). Additionally, the downstream target of P90rsk, CREB, as well as another downstream target of ERK1/2, activating transcription factor-1 (ATF1), were unaffected by the presence of the PKC-Z isoform (Figure 4b and data not shown). As was the case for pERK (Figure 3) , total P90rsk and CREB were unchanged by the presence of PKC-Z. Together with the data in Figure 3 , these data strongly suggest that PKC-Z specifically activates a MEK1/pERK1/2 phosphorylation cascade.
Inhibition of MEK1 and PKC abolish PMA-stimulated Elk-1 transcription activity and PKC-Z-mediated proliferation To identify downstream targets of PKC-Z that could underlie PMA-mediated proliferation, we asked if the ability of PMA to stimulate Elk-1 transcription correlated with the proliferative response. As shown (Figure 2) , PMA-stimulated Elk-1-mediated transcription in a PKC-Z-dependent manner. If the phosphorylation cascade suggested above did mediate the proliferative response, then treatment with BIM and U0126 should attenuate Elk-1 transcriptional activity and proliferation. BIM and U0126 did both (Figures 5a  and b) . Pretreatment with BIM alone had no effect on basal levels of transcription or proliferation, it did block the PMA-induced transcriptional activity of Elk-1 and the proliferative response (Figure 5a and b) . We have previously shown that antisense directed against PKC-Z reduces PMA-induced proliferation of U251 cells (Hussaini et al., 2000) . Collectively, the data suggest that PKC-Z regulates proliferation in U-251, and that the proliferative response involves Elk-1.
Treatment of U-251 cells with the MEK inhibitor U0126 generated a pattern similar to BIM. However, U0126 blocked basal transcription, and reduced PMA-induced proliferation more so than BIM. Together with data previously reported (Hussaini et al., 2000) , the data strongly suggest that PMA activation of PKC-Z leads to MEK activation, which targets the transcription factor Elk-1.
PKC-Z is required for PMA-and EGF-stimulated proliferation PMA-induced proliferation in wild-type cells (Figure 6a ), but repressed it in cells overexpressing the dominantnegative PKC-Z, U251-PKC-ZKR (Figure 6b ). To assess the physiological relevance of this effect, we measured the response to EGF stimulation. Like PMA, EGF stimulated proliferation; however, in the absence of PKC-Z kinase activity, it failed to have an effect. Thus, in U-251 cells PKC-Z is required for PMA-and EGFinduced proliferative responses.
Reduced levels of Elk-1 diminish the U-251 mitogenic response to PMA and EGF. To determine if reduction of Elk-1 in U-251 cells would be associated with decreased proliferation, cells were transfected with siRNA directed against Elk-1 (400 or 600 nM). Transfection of Elk-1 siRNA reduced levels of Elk-1 (Figure 7a ). Reduced Elk-1 abolished the proliferative response to PMA (Figure 7b ), in cells from the same experiment (Figure 7a ). To determine if reduced Elk-1 effected changes in other PMA targets, we assessed levels of P90rsk and CREB expression. inhibitor U0126 markedly reduced pERK1/2 levels, which were also reduced in the presence of the PKC inhibitor, BIM. Antibody dilutions used were pERK1/2 (1:5000) and total ERK (1:1000).
Figure 4 PKC-Z fails to alter pP90rsk or pCREB levels. The presence of PKC-Z does not affect the PMA-induced levels of pP90rsk (a) or pCREB (b). PMA treatment also does not alter the levels of total P90rsk (a) or CREB (b). Antibody dilutions for P90rsk, CREB and their corresponding phosphorylated forms were all 1:1000.
Elk-1 mediates PKC-g-induced proliferation RM Uht et al
Neither was changed by siRNA. Reduced Elk-1 also failed to alter levels of the nuclear protein, nucleolin. Thus, reduction of Elk-1 did not exert a generalized effect on nuclear integrity (Figure 7c ). Lastly, to determine if diminished Elk-1 levels would alter the response to a physiologically relevant ligand, we performed the proliferation experiment shown in Figure 6b with EGF. EGF-stimulated proliferation was eliminated in the presence of siRNA directed against Elk-1 (Figure 7d ). Together, the data strongly support the hypothesis that Elk-1 is required for PMA-and EGF-stimulated proliferation of U-251 glioblastoma cells.
Discussion
GBM is a rapidly growing and lethal brain tumor. Because it has a high proliferation rate, elucidating proliferative mechanisms is of significant importance in the development of long-term management.
Previous studies have implicated PKC in the regulation of glioblastoma growth (Baltuch et al., 1995; Sharif and Sharif, 1999) ; the results are conflicting as to how this regulation is mediated (Baltuch and Yong, 1996; Dooley et al., 1998; Zellner et al., 1998) . One explanation for the conflict is that individual glioblastomas express unique profiles of PKC isozymes (Couldwell et al., 1990; Pollack et al., 1991; Szaniawska et al., 1996) . PKC-a has been implicated in proliferation and in suppression of apoptosis (Shen and Glazer, 1998) , whereas PKC-g augments anchorage-independent growth in cell culture (Mishima et al., 1994) .
Expression of PKC-Z correlates with the growth properties of two glioblastoma cell lines: U-251 cells and the stably transfected U-1242-PKC-Z cell line (Hussaini et al., 2000) . Furthermore, PKC-Z partially increases cell proliferation via Akt, and the mammalian target of rapamycin (mTOR) (Aeder et al., 2004) . To date, the signaling pathways by which PKC-Z increases proliferation via MAPK cascades and their transcription factor targets had not been elucidated.
We designed studies to determine whether c-jun and/ or c-fos are direct or indirect downstream targets of PKC-Z, and if their activation would lead to enhanced proliferation. PKC-Z expression failed to induce c-junor c-fos-mediated transcriptional activity or proliferation in U-251 cells (Figures 1, 2 , and data not shown). Rather, transfected c-jun reduced PMA stimulation of transcription and proliferation. Thus, these AP-1 family members fail to stimulate transcription and proliferation Cells were transfected with GAL DBD:Elk-1 expression vector (5 mg) and the (GAL-RE) 5 reporter construct (5 mg). They were pretreated with BIM (1 mM) or U0126 (10 mM) for 1 h before PMA treatment (100 nM) for 48 h. Cells were assayed for luciferase activity. (a) Although the PKC inhibitor BIM had no effect on basal transcriptional activity, it blocked PMA-stimulated activity. The MEK1 inhibitor (U0126) abrogated basal activity and blocked the PMA response. (b) The mitogenic response to both inhibitors closely paralleled that of the transcriptional response, with the exception that treatment with the MEK1 inhibitor reduced, but did not abrogate, basal mitogenic activity. (*) The U0126 treatment differs from control (Po0.001). (**) In the presence of PMA, BIM and U0126 differ from PMA alone (Po0.001).
Elk-1 mediates PKC-g-induced proliferation RM Uht et al in a PKC-Z-dependent manner. c-jun may have an effect in vivo; however, it may be reduction of transcription and proliferation, rather than stimulation.
In distinction to c-jun and c-fos, there was high concordance of PKC-Z expression with the ability of Elk-1 to activate transcription (Figure 2b-d) . We examined the ability of PKC-Z to regulate ERK, which phosphorylates Elk. The ability of PKC-Z to increase ERK phosphorylation in PKC-Z-positive cells was blocked by the MEK1 inhibitor U0126 and by the PKC inhibitor BIM (Figure 3) . Because different signaltransduction pathways may display considerable overlap, we determined whether PMA stimulation of other downstream targets would vary by PKC-Z cellular status. The phosphorylation state of P90rsk, its substrate CREB and the transcription factor ATF-1 fail to correlate with cellular levels of PKC-Z (Figure 4 and not shown). Thus, the effect of PKC-Z is confined to ERK.
To determine if the putative PKC-Z-ERK-Elk pathway could have physiologic relevance, we analysed the transcriptional and proliferative responses to BIM and U0126. The pattern of responses closely paralleled the pattern of ERK1/2 phosphorylation, particularly when they were used to block the effects of PMA (Figures 3b  and 5) . Thus, the phosphorylation state of ERK1/2 tightly correlates both with Elk-1 transcriptional activity and the degree of proliferation in glioblastoma cells that express PKC-Z.
Lastly, we sought to strengthen the correlation between PKC-Z, Elk-1 and proliferation. In U-251 cells, we examined the effect of opposing endogenous PKC-Z with a PKC-Z dominant-negative and of reducing endogenous Elk-1 levels. The ability of PMA and EGF to stimulate U-251 proliferation, was completely dependent on the presence of unopposed wild-type PKC-Z (Figure 6 ). PMA inhibited and EGF had no effect on cell proliferation which overexpress the PKC-ZKR mutant. These data corroborate the conclusion drawn by Hussaini et al. (2000) that PKC-Z is required for proliferation of more than one glioblastoma cell line. To corroborate the Elk-1 requirement for proliferation, we used siRNA to knock down endogenous levels in U-251 cells (Figure 7a) . Reduction of Elk eliminated the ability of PMA and EGF to stimulate proliferation (Figure 7b and d) . Taken together, the data substantiate a model in which activation of PKC-Z leads to a series of phosphorylation events in which MEK1/ERK/Elk-1 are sequentially activated. Activation of Elk-1 leads to increased transcriptional activity and to increased proliferation. Elk-1 gene targets are unknown.
PKC isoforms exert unique effects on various biological processes. This specificity may confer an advantage for the development of therapies directed toward individual GBMs. For example, a patient's tumor might be phenotyped both for the expression of a PKC isoform and for Elk-1. Thus, drugs could be designed to target PKC-Z alone, or in combination with agents designed to block Elk-1.
Lastly, other modifications of Elk-1 likely determine its net potential for activation. In particular, Yang et al. (2003) have shown that the degree to which Elk-1 activates transcription is a function not only of phosphorylation of its activation domain but also of de-SUMOylation of one of its repression domains . Additionally, other Ets family members have been shown to be post-translationally modified by acetylation (Ets1), glycosylation (Elf-1) and other moieties (reviewed by Tootle and Rebay, 2005) . Thus, numerous modifications of Elk-1 may play a role in the oncogenesis of GBM.
Materials and methods

Antibodies and pharmacological reagents
These were obtained as follows: anti-tubulin (DMA1) (Sigma Company, St Louis, MO, USA); phospho-ERK1/2 (Promega, Madison, WI, USA); total ERK1/2, pP90rsk (Ser380) and pCREB (Ser133) (Cell Signaling Technology, Beverly, MA, USA); total P90rsk and total CREB (Santa Cruz Biotechnology, Santa Cruz, CA, USA). U-0126 and BIM were obtained from Calbiochem (La Jolla, CA, USA).
Plasmids
The following expression vectors were obtained from UCSF: c-jun (Turner and Tjian, 1989) , Gal-c-jun, Gal-c-jun 63/73 and Gal-Elk-1 (originally from Richard Treisman). Coll73: luciferase, (GAL-RE) 5 : luciferase and actin b-galactosidase reporter constructs have been described (Lopez et al., 1993; Uht et al., 1997; Webb et al., 1999) .
Cell cultures
Human U-251 MG and U-1242 MG cell lines were originally supplied by Dr D Bigner (Duke University) and Dr AJ Yates (Ohio State University), respectively. Both cell lines were isolated from human glioblastomas and various characteristics have been described (Bigner et al., 1981; Bongcam-Rudloff et al., 1991; Uhrbom et al., 1997; Hussaini et al., 1999) . U-1242-Z cells are U-1242 cells that stably express PKC-Z (Hussaini et al., 2000) . U-251-PKC-ZKR cells are U-251 cells that have been virally infected with a PKC-Z dominantnegative, a PKC-Z bearing a lysine-to-arginine mutation in the kinase domain (Aeder et al., 2004) . Both lines were determined to be free of mycoplasma on a regular basis, using reagents from Gen-Probe Inc. (San Diego, CA, USA). Cells were grown in minimal essential medium-alpha modification (a-MEM with 10% defined fetal bovine serum (Hyclone, Logan, UT, USA) and 20 mg/ml bovine zinc-insulin (25.7 IU/mg, Sigma, St Louis, MO, USA). Confluent cultures (80-100%) were washed with serum-free medium before PMA treatment (100 nM). For proliferation experiments, 3 H-thymidine was added.
Transient transfections U-251 wt, U-1242 wt and U-1242-Z were grown to 90-100% confluence. Trypsinized cells were suspended in electroporation buffer (10% glucose and 10 mg/ml BioBrene detergent in phosphate-buffered saline (PBS); Applied Biosystems, Foster City, CA, USA) along with indicated plasmids. Electroporation was performed with a Biorad Gene Pulser set at 960 mFD and 0.25 kV using 0.4 cm gap cuvettes (Biorad, cat. no. 1652088). Cuvettes contained 0.5 ml resuspended cells and the indicated amount of plasmid (1.5 Â 10 6 cells, 18 mg total DNA). After electroporation, 0.5 ml of media (MEM with 10% fetal bovine serum (FBS)) was added to each cuvette. Cells were diluted in 12 ml media (MEM with 10% FBS), plated and then incubated at 371C and 5.5% CO 2 overnight before treatment. Treatments consisted of either the PKC inhibitor BIM (1.0 mM) or the MEK inhibitor U0126 (10 mM) for 60 min followed by treatment with PMA (100 nM; Sigma Company, St Louis, MO, USA) or vehicle dimethylsulfoxide (DMSO) for 24 h.
Luciferase and b-galactosidase Assays Cells were washed with PBS before the addition of cell lysis buffer (25 mM Tris HCl (pH 7.8), 2 mM 1,2 diaminocyclohexane N,N,N,N-tetracetic acid, 1% Triton X-100 and 10% glycerol; with dithiothreitol (DTT) (2 mM) added freshly). This was followed by a freeze/thaw cycle (À801C/room temperature). Lysates were transferred to pre-chilled tubes (1.5 ml) and centrifuged at 8000 r.p.m. in a Sorvall Biofuge fresco table top centrifuge rotor (no. 7500 3325) at 41C for 2 min. Luciferase and b-galactosidase activity were assayed with the Promega Luciferase Assay System and Tropix reagents (Galacto Reaction Buffer with Galacton-plus substrate and Accelerator II), respectively. Light units were measured by an Opti Comp II automated luminometer (MGM instruments, Hamden, CT, USA). Protein concentrations were determined with bicinchoninic acid (BCA) Protein Assay Reagent A (Pierce, Rockford, IL, USA) as described (Hussaini et al., 2000) .
Kinase phosphorylation analysis MAPK phosphorylation was assessed in cells cultured in serum-free medium for 24 h. Cells were exposed to BIM (1.0 mM) or U0126 (10 mM) for 60 min before PMA treatment (100 nM), for 30 min. Ice-cold PBS containing 0.2 mM sodium orthovanadate terminated the incubation. For wholecell extracts, cells were lysed with 1.0% NP-40, 50 mM 2-hydroxyethylpiperazine-N 0 -2-ethanesulphonic acid (HEPES), 100 mM NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), 1 mg/ml leupetin, 2 mg/ml aprotinin, 0.4 mg/ml sodium fluoride, 5 mg/ml DTT and 0.2 mM sodium orthovanadate. The lysate was centrifuged at 14 000 r.p.m. in a Sorvall microfuge and rotor (as above) for 15 min; the supernatant was collected and analysed by Western blot analysis as described previously (Hussaini et al., 2000) . For nuclear extracts, a nuclear extraction kit from Activemotif (Carlsbad, CA, USA) was used. Briefly, cells were washed with a PBS buffer containing phosphatase inhibitors. To isolate nuclei, the cells were pelleted and resuspended in a hypotonic buffer, and a detergent was added. After centrifugation, the pellet was incubated with Complete Lysis Buffer, vortexed and centrifuged. The supernatant containing the nuclear extract was kept for analysis.
3 H-thymidine incorporation Briefly, as reported previously (Hussaini et al., 1999) , cells were treated with PMA (100 nM) for 20 h, washed with calciumand magnesium-free PBS and subsequently pulsed with 3 H-thymidine (2 mCi/ml for 2 h at 371C). Cells were lysed in 1 N NaOH. siRNA transfections and Western blot analysis These were performed similarly to those reported (Amos et al., 2005) . Briefly, a 'smart pool' of purified Elk-1 siRNA oligomers (Dharmacon Inc., Lafayette, CO, USA) was transfected into U-251 cells using the Amaxa Nucleofector system (Amaxa, Gaithersburg, MD, USA). Trypsinized cells were resuspended in Amaxa Nucleofector solution V at a density of 2 Â 10 6 cells/100 ml of solution, and mixed with siRNA. Cells were transfected using the F15 pulsing program. After electroporation, cells were suspended in 4.9 ml of a-MEM including 10% fetal bovine serum and then incubated at 371C. Cell lysates or nuclear extracts (200 mg of proteins/lane) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) using 8% polyacrylamide gels. Proteins were electroblotted onto a nitrocellulose membrane, then probed with antibodies, as indicated. After incubation with peroxidase-conjugated anti-mouse antibodies, detection was effected by chemiluminescent reagents, as described by the manufacturer (Amersham, Piscataway, NJ, USA).
Data analysis
Luciferase data were corrected for the efficiency of transfection by dividing luciferase relative luciferase unit (RLU) by b-galactosidase RLU. Resultant values were normalized for protein concentration. The mean and standard error of the mean (s.e.m.) were calculated for each triplicate point by using Prism VI (Graphpad Software, San Diego, CA, USA). Each experiment was performed minimum of three times. The level of significance was taken at Po0.05.
